Flumazenil is a parenteral benzodiazepine antagonist and an imidazobenzodiazepine derivative. This product is used to reverse benzodiazepine-induced sedation during anesthesia and to treat benzodiazepine overdose. It can antagonize the sedative effects of zolpidem and eszopiclone. Because the solution is highly irritating, it is administered by rapid intravenous injection with precautions to avoid extravasation. In pediatric patients, the intravenous formulation has been administered via intranasal and rectal routes, but these routes are not FDA-approved. Storage information such as required temperature or light protection is not listed in the supplied data. The intravenous formulation is highly irritating, and care should be taken to avoid extravasation during administration. The product can cause resedation; seizures have been reported and may occur in certain populations, including those with hepatic impairment or benzodiazepine dependence or in overdose situations. Abrupt interruption of benzodiazepine effect can precipitate withdrawal, including seizures, particularly in patients with chronic benzodiazepine use. Other adverse effects include dizziness, headache, agitation, nervousness, and various sensory, respiratory, cardiovascular, and gastrointestinal events. This description is for informational purposes only and is not clinical advice.